Pratibha S. Binder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pratibha S. Binder has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Ramez N. Eskander
University of California San Diego, Rebecca and John Moores Cancer Center, Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Gynecologic Oncology, San Diego, CA
3 shared publications - Abigail S. Zamorano
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, USA
1 shared publication - Allison L. Brodsky
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States
1 shared publication - Andrew C. Picel
Division of Interventional Radiology, Department of Radiology, Stanford University, Stanford, USA
1 shared publication Anjali Hari
1 shared publication- Anne C. Roberts
Department of Radiology, University of California San Diego, La Jolla, CA 92093, USA
1 shared publication
Latest Publications
- 1 May 2026
- Published by Bentham Science Publishers Ltd. in Current Women s Health Reviews
- Vol. 22 (4) , 1-6
Narcotic Waste Associated with Postoperative Patient-Controlled Analgesia in Gynecologic Oncology Surgery: A Retrospective Review
Introduction: This study aimed to quantify narcotic waste associated with patientcontrolled analgesia during the immediate post-operative period following gynecologic oncology surgery. Methods: We identified women who underwent abdominal surgery with a gynecologic oncologist at a single institution and reviewed their medical records retrospectively. The information on demographics, surgery, pathology, pain control methods, and narcotic use was collected. Narcotic waste is defined as narcotics that are opened, not used, and cannot be recycled. Statistical analysis included medians, frequencies, Mann-Whitney U tests, and Kruskal-Wallis tests with a set p-value of <0.05. Results: A total of 494 surgeries performed between 2019 and 2021 were reviewed, of which 100 (20.2%) patients received patient-controlled analgesia with hydromorphone post-operatively. The median waste for patient-controlled analgesia was 61% of the medication prepared. There was no statistically significant difference in patient-controlled analgesia waste when controlling for preoperative medications or regional blocks (p = 0.5). When surgeries were further categorized based on complexity, no significant difference in post-operative narcotic waste was identified (p=0.07). Sixty percent of patient-controlled analgesia pumps were discontinued on the first postoperative day. Six percent of patients did not use the patient-controlled analgesia at all (100% waste). Discussion: Clinically significant narcotic waste was identified post-operatively in gynecologic oncology patients who received a hydromorphone patient-controlled analgesia pump. Conclusion: Surgeons and anesthesiologists may consider focusing on multimodal pain regimens, reducing patient-controlled analgesia use, and prescribing narcotics on demand and when indicated.
- 1 May 2026
- Published by Bentham Science Publishers Ltd. in Current Women s Health Reviews
- Vol. 22 (4) , 1-6
Narcotic Waste Associated with Postoperative Patient-Controlled Analgesia in Gynecologic Oncology Surgery: A Retrospective Review
Introduction: This study aimed to quantify narcotic waste associated with patientcontrolled analgesia during the immediate post-operative period following gynecologic oncology surgery. Methods: We identified women who underwent abdominal surgery with a gynecologic oncologist at a single institution and reviewed their medical records retrospectively. The information on demographics, surgery, pathology, pain control methods, and narcotic use was collected. Narcotic waste is defined as narcotics that are opened, not used, and cannot be recycled. Statistical analysis included medians, frequencies, Mann-Whitney U tests, and Kruskal-Wallis tests with a set p-value of <0.05. Results: A total of 494 surgeries performed between 2019 and 2021 were reviewed, of which 100 (20.2%) patients received patient-controlled analgesia with hydromorphone post-operatively. The median waste for patient-controlled analgesia was 61% of the medication prepared. There was no statistically significant difference in patient-controlled analgesia waste when controlling for preoperative medications or regional blocks (p = 0.5). When surgeries were further categorized based on complexity, no significant difference in post-operative narcotic waste was identified (p=0.07). Sixty percent of patient-controlled analgesia pumps were discontinued on the first postoperative day. Six percent of patients did not use the patient-controlled analgesia at all (100% waste). Discussion: Clinically significant narcotic waste was identified post-operatively in gynecologic oncology patients who received a hydromorphone patient-controlled analgesia pump. Conclusion: Surgeons and anesthesiologists may consider focusing on multimodal pain regimens, reducing patient-controlled analgesia use, and prescribing narcotics on demand and when indicated.
- Open Access
Recent Therapeutic Advances in Gynecologic Oncology: A Review
Gynecologic malignancies have high incidence rates both nationally and internationally, and cervical, endometrial, and ovarian cancers account for high mortality rates worldwide. Significant research is ongoing to develop targeted therapies to address unmet needs in the field and improve patient outcomes. As tumors mutate and progress through traditional lines of treatment, new therapies must be developed to overcome resistance and target cancer-specific receptors and mutations. Recent advances in the development of immunotherapy and antibody–drug conjugates have resulted in compelling and clinically meaningful results in cervical, endometrial, and ovarian cancers. In the last decade, several immunotherapy agents have received FDA approval or NCCN guideline recommendation for the treatment of gynecologic malignancies, including dostarlimab for advanced or recurrent endometrial cancer and pembrolizumab for advanced or recurrent cervical and endometrial cancers. Several other immunotherapeutic agents are under active investigation. Development of antibody–drug conjugates including tisotumab vedotin in cervical cancer, mirvetuximab soravtansine in ovarian cancer, and trastuzumab deruxtecan in multiple gynecologic cancers has translated into exciting efficacy signals, prompting full drug approvals and additional investigation. This article aims to review recent novel advances in targeted treatments for gynecologic malignancies, highlighting the trials and data underlying these novel interventions.
Open AccessRecent Therapeutic Advances in Gynecologic Oncology: A Review
Gynecologic malignancies have high incidence rates both nationally and internationally, and cervical, endometrial, and ovarian cancers account for high mortality rates worldwide. Significant research is ongoing to develop targeted therapies to address unmet needs in the field and improve patient outcomes. As tumors mutate and progress through traditional lines of treatment, new therapies must be developed to overcome resistance and target cancer-specific receptors and mutations. Recent advances in the development of immunotherapy and antibody–drug conjugates have resulted in compelling and clinically meaningful results in cervical, endometrial, and ovarian cancers. In the last decade, several immunotherapy agents have received FDA approval or NCCN guideline recommendation for the treatment of gynecologic malignancies, including dostarlimab for advanced or recurrent endometrial cancer and pembrolizumab for advanced or recurrent cervical and endometrial cancers. Several other immunotherapeutic agents are under active investigation. Development of antibody–drug conjugates including tisotumab vedotin in cervical cancer, mirvetuximab soravtansine in ovarian cancer, and trastuzumab deruxtecan in multiple gynecologic cancers has translated into exciting efficacy signals, prompting full drug approvals and additional investigation. This article aims to review recent novel advances in targeted treatments for gynecologic malignancies, highlighting the trials and data underlying these novel interventions.
- Open Access
- 20 June 2023
- Published by Edorium Journals Pvt. Ltd. in Journal of Case Reports and Images in Obstetrics and Gynecology
- Vol. 9 (1) , 83-86
Ovarian mucinous adenocarcinoma and false negative frozen pathology: A case report and review of the literature
Introduction: In this case report we discuss the presentation and management of a woman with a large adnexal mass. Case Report: This report describes a 32-year-old year healthy woman who presented with four months of increasing abdominal fullness. Computed tomography (CT) imaging showed a 34 cm fluid-filled left adnexal mass with few thin septations. Tumor markers were within normal limits. She strongly desired minimally invasive surgery in the setting of low concern for malignancy. A mini-laparotomy was performed, purse string sutures were placed through the cyst wall, and fluid was aspirated with minimal spillage. Her left tube and ovary were resected laparoscopically. Intraoperative frozen pathology returned as mucinous cystadenoma with some areas of atypia. Final pathology resulted with Grade 2 mucinous adenocarcinoma and she was taken back to the operating room for a surgical staging procedure. Pathology from her laparoscopic staging surgery was benign. She underwent chemotherapy with carboplatin/paclitaxel for Stage 1C1, Grade 2 mucinous adenocarcinoma of the ovary based on intra-operative spillage. Conclusion: Despite reassuring imaging and tumor markers, particularly in the setting of frozen pathology with low concern for malignancy, final pathology may indicate carcinoma. Although the accuracy of intra-operative frozen pathology is generally high, both gynecologic oncologists and non-oncologic gynecologists should be aware of the limitations of the test and counsel patients that the final pathology may be discordant. Appropriate counseling about the risk of intra-operative spillage and subsequent upstaging is of particular importance.
- 20 June 2023
- Published by Edorium Journals Pvt. Ltd. in Journal of Case Reports and Images in Obstetrics and Gynecology
- Vol. 9 (1) , 83-86
Open AccessOvarian mucinous adenocarcinoma and false negative frozen pathology: A case report and review of the literature
Introduction: In this case report we discuss the presentation and management of a woman with a large adnexal mass. Case Report: This report describes a 32-year-old year healthy woman who presented with four months of increasing abdominal fullness. Computed tomography (CT) imaging showed a 34 cm fluid-filled left adnexal mass with few thin septations. Tumor markers were within normal limits. She strongly desired minimally invasive surgery in the setting of low concern for malignancy. A mini-laparotomy was performed, purse string sutures were placed through the cyst wall, and fluid was aspirated with minimal spillage. Her left tube and ovary were resected laparoscopically. Intraoperative frozen pathology returned as mucinous cystadenoma with some areas of atypia. Final pathology resulted with Grade 2 mucinous adenocarcinoma and she was taken back to the operating room for a surgical staging procedure. Pathology from her laparoscopic staging surgery was benign. She underwent chemotherapy with carboplatin/paclitaxel for Stage 1C1, Grade 2 mucinous adenocarcinoma of the ovary based on intra-operative spillage. Conclusion: Despite reassuring imaging and tumor markers, particularly in the setting of frozen pathology with low concern for malignancy, final pathology may indicate carcinoma. Although the accuracy of intra-operative frozen pathology is generally high, both gynecologic oncologists and non-oncologic gynecologists should be aware of the limitations of the test and counsel patients that the final pathology may be discordant. Appropriate counseling about the risk of intra-operative spillage and subsequent upstaging is of particular importance.
- 9 September 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166, S41
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Outcomes Across Three Academic Institutes Among Frail and Non-Frail Patients (064)
- 9 September 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166, S41
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Outcomes Across Three Academic Institutes Among Frail and Non-Frail Patients (064)
- Open Access
- 12 March 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-10
The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer
Ovarian cancer is initially responsive to frontline chemotherapy. Unfortunately, it often recurs and becomes resistant to available therapies and the survival rate for advanced and recurrent ovarian cancer is unacceptably low. We thus hypothesized that it would be possible to achieve more durable treatment responses by combining cisplatin chemotherapy with SW IV-134, a cancer-targeted peptide mimetic and inducer of cell death. SW IV-134 is a recently developed small molecule conjugate linking a sigma-2 ligand with a peptide analog (mimetic) of the intrinsic death pathway activator SMAC (second-mitochondria activator of caspases). The sigma-2 receptor is overexpressed in ovarian cancer and the sigma-2 ligand portion of the conjugate facilitates cancer selectivity. The effector portion of the conjugate is expected to synergize with cisplatin chemotherapy and the cancer selectivity is expected to reduce putative off-target toxicities. Ovarian cancer cell lines were treated with cisplatin alone, SW IV-134 alone and a combination of the two drugs. Treatment efficacy was determined using luminescent cell viability assays. Caspase-3/7, − 8 and − 9 activities were measured as complementary indicators of death pathway activation. Syngeneic mouse models and patient-derived xenograft (PDX) models of human ovarian cancer were studied for response to SW IV-134 and cisplatin monotherapy as well as combination therapy. Efficacy of the therapy was measured by tumor growth rate and survival as the primary readouts. Potential drug related toxicities were assessed at necropsy. The combination treatment was consistently superior in multiple cell lines when compared to the single agents in vitro. The expected mechanism of tumor cell death, such as caspase activation, was confirmed using luminescent and flow cytometry-based assay systems. Combination therapy proved to be superior in both syngeneic and PDX-based murine models of ovarian cancer. Most notably, combination therapy resulted in a complete resolution of established tumors in all study animals in a patient-derived xenograft model of ovarian cancer. The addition of SW IV-134 in combination with cisplatin chemotherapy represents a promising treatment option that warrants further pre-clinical development and evaluation as a therapy for women with advanced ovarian cancer.
- 12 March 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-10
Open AccessThe targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer
Ovarian cancer is initially responsive to frontline chemotherapy. Unfortunately, it often recurs and becomes resistant to available therapies and the survival rate for advanced and recurrent ovarian cancer is unacceptably low. We thus hypothesized that it would be possible to achieve more durable treatment responses by combining cisplatin chemotherapy with SW IV-134, a cancer-targeted peptide mimetic and inducer of cell death. SW IV-134 is a recently developed small molecule conjugate linking a sigma-2 ligand with a peptide analog (mimetic) of the intrinsic death pathway activator SMAC (second-mitochondria activator of caspases). The sigma-2 receptor is overexpressed in ovarian cancer and the sigma-2 ligand portion of the conjugate facilitates cancer selectivity. The effector portion of the conjugate is expected to synergize with cisplatin chemotherapy and the cancer selectivity is expected to reduce putative off-target toxicities. Ovarian cancer cell lines were treated with cisplatin alone, SW IV-134 alone and a combination of the two drugs. Treatment efficacy was determined using luminescent cell viability assays. Caspase-3/7, − 8 and − 9 activities were measured as complementary indicators of death pathway activation. Syngeneic mouse models and patient-derived xenograft (PDX) models of human ovarian cancer were studied for response to SW IV-134 and cisplatin monotherapy as well as combination therapy. Efficacy of the therapy was measured by tumor growth rate and survival as the primary readouts. Potential drug related toxicities were assessed at necropsy. The combination treatment was consistently superior in multiple cell lines when compared to the single agents in vitro. The expected mechanism of tumor cell death, such as caspase activation, was confirmed using luminescent and flow cytometry-based assay systems. Combination therapy proved to be superior in both syngeneic and PDX-based murine models of ovarian cancer. Most notably, combination therapy resulted in a complete resolution of established tumors in all study animals in a patient-derived xenograft model of ovarian cancer. The addition of SW IV-134 in combination with cisplatin chemotherapy represents a promising treatment option that warrants further pre-clinical development and evaluation as a therapy for women with advanced ovarian cancer.
- Open Access
- 14 December 2021
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 39, 100901
Pregnancy-associated large pelvic desmoid tumor: A case report of fetal-protective strategies and fertility preservation
- 14 December 2021
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 39, 100901
Open AccessPregnancy-associated large pelvic desmoid tumor: A case report of fetal-protective strategies and fertility preservation
- Open Access
- 1 October 2021
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 225 (4) , 442.e1-442.e10
Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization: the PASTIME protocol
- 1 October 2021
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 225 (4) , 442.e1-442.e10
Open AccessPlacenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization: the PASTIME protocol